MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain Cancer

MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Department of Neurosurgery at Kiel University Hospital (UKSH), headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers.

After the start of commercial treatments of brain cancers at the University Hospital in Munster in February, this marks another milestone for MagForce with now two world class medical centers offering NanoTherm(TM) therapy also in the commercial setting.

"Since we announced the first commercial patient in February this year based on our European approval for the treatment of brain cancer, we have observed a significantly increased interest of patients, national as well as international, for the treatment with our innovative NanoTherm(TM) therapy in Germany. We are especially pleased with the successful interaction with the key opinion leaders in the medical community. Preparations for the approval process in the US both for brain cancer and prostate cancer are well on track, hence, 2015 is set to be a transformational year for MagForce, marking first commercial revenues and global expansion," commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.